| Factor Information | |
|---|---|
| Data ID | 222 |
| Factor | seraphin(tolerability) |
| Description | In patients with corrected CHD-PAH, 4 (8.0%) placebo patients and 5 (8.3%) selexipag patients discontinued their treatment pre-maturely due to an adverse event(AE) |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | treatment |
| Objective | CHD-PAH patients |
| Conclusion | These post-hoc analyses suggest that selexipag may delay dis- ease progression and is well tolerated in patients with corrected CHD-PAH. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 430 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/PTA |
| Reference | |
|---|---|
| PMID | 30632656 |
| Year | 2019 |
| Title | Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study |
| Sample | ||
|---|---|---|
| Population | adults | |
| Source | enroll at sites in 26 countries | |
| Region | Switzerland, Lansanne USA, TX/MI/CA Ireland, Dubin UK, London | |
| Method | The double-blind treatment | |
| Race | Asian European American Austrclian | |
| Disease History | 60(Selexipag) | |
| Treatment History | 50(Placebo) | |
| Group | Selexipag(Treatment) | Placebo(Control) |
| Number | 60 | 50 |
| Age | 40.2±15.4 years | 40.3±14.8 years |
| Gender (Male: Female) | 14:46 | 8:42 |
| Marker Level | discontinued their treatment pre-maturely due to an AE:8.3% | discontinued their treatment pre-maturely due to an AE:8.0% |
